AnaptysBio, Inc. announced appointment of Daniel Faga as interim president, effective immediately. Mr. Faga currently serves on the company's board of directors and will succeed Hamza Suria, who has stepped down from his role as president and as board director.  Mr. Suria will continue to support the company in an advisory capacity. Mr. Faga has been a member of AnaptysBio's board of directors since December 2021.

Most recently, Faga was chief operating officer at Mirati Therapeutics. Prior to Mirati, Dan was chief business officer at Spark Therapeutics. Previously, Dan was managing director and founding member of Centerview Partner's healthcare advisory practice.